Article

Poor efficacy of immune checkpoint inhibitors plus chemotherapy in the lung cancer patients with EGFR/ERBB2 exon 20 insertion

2022-08-18

Abstract excerpt

<h4>Background: </h4> EGFR and ERBB2 exon 20 insertion (Ex20ins) comprised a small subset of patients with EGFR mutations. The efficacy of immune checkpoint inhibitors (ICIs), especially in combination with chemotherapy, for these patients was still controversial. <h4>Methods: </h4>: This retrospective study enrolled lung cancer patients harboring either EGFR or ERBB2 Ex20ins mutations. For comparison, lung cancer...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4f4507c2-dcf6-5901-b613-40b257afc2bb
DOI: 10.21203/rs.3.rs-1911438/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Poor efficacy of immune checkpoint inhibitors plus chemotherapy in the lung cancer patients with EGFR/ERBB2 exon 20 insertionDOI 10.21203/rs.3.rs-1911438/v1Read

EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectivesSemantic proximity Read

Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimenSemantic proximity Read

Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapy.Semantic proximity Read

Molecular heterogeneity and treatment outcome of EGFR exon 20 insertion mutations in Chinese patients with advanced non-small cell lung cancer: insights from a large-scale real-world study.Semantic proximity Read

Immune microenvironment features and efficacy of PD‐1/PD‐L1 blockade in non‐small cell lung cancer patients with EGFR or HER2 exon 20 insertionsSemantic proximity Read

Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions.Semantic proximity Read

Comparative Clinical Outcomes Between EGFR Ex20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors.Semantic proximity Read

The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidationSemantic proximity Read

Characteristics, treatment patterns, and clinical outcomes in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions.Semantic proximity Read

[Advances in the Treatment of EGFR Exon 20ins Mutant NSCLC].Semantic proximity Read

EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation.Semantic proximity Read

[EGFR Exon 20 Insertion Mutation: Research Status and New Treatment Strategies].Semantic proximity Read